The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study
Objective
This trial evaluated the efficacy of probiotics L. paracasei MSMC39-1 and B. animalis TA-1 in modulating gut microbiota and reducing metabolic syndrome risk factors.
Method
This study was a randomized, double-blind, parallel-controlled trial. Participants were randomly assigned to two groups, and data collection included medical history, physical examination, blood tests, and stool sample analysis at baseline and after 12 weeks of intervention. Stool samples, anthropometric measurements, and blood chemistry profiles were obtained at both time points to assess the outcomes of the intervention.
Results
The probiotics group demonstrated significant improvements compared to the placebo group, including a marked reduction in low-density lipoprotein cholesterol levels, body weight, body mass index, waist circumference, systolic blood pressure, and total cholesterol. Gut microbiome analysis revealed significant differences in beta diversity post-intervention, with increased prevalence of Blautia, Roseburia, Collinsella, and Ruminococcus in the probiotics group. Predicted functional changes in the probiotics group included enhanced ATP-binding cassette (ABC) transporter activity, RNA transport, unsaturated fatty acid biosynthesis, glycerophospholipid metabolism, and pyruvate metabolism. These findings highlight the probiotics’ potential in improving cardiovascular risk factors and modulating gut microbiota composition and function.
Conclusion
In summary, this study showed that Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics effectively reduced metabolic syndrome risk factors, including significant decreases in low-density lipoprotein cholesterol, triglycerides, and total cholesterol. Improvements in body weight, body mass index, and waist circumference were observed exclusively in the probiotics group. Gut microbiome analysis revealed enhanced beta-diversity and increased abundance of short-chain fatty acid-producing bacteria (Blautia, Roseburia, Collinsella, and Ruminococcus), along with predicted functional changes in ribonucleic acid transport, ATP-binding cassette transporters, and lipid metabolism pathways, supporting the probiotics’ role in metabolic regulation.
Data Availability Statement: The raw sequence data are available under BioSample SAMN42867309 and BioProject PRJNA1141093.
Funding: the study was supported by the Chiangmai Bioveggie and National Innovation Agency (grant number PE0201-02-64-11-0252) and the Center of Excellence in Probiotics at Srinakharinwirot University (grant number 324/2565).
Clinical Trial Reg: TCTR20230505002
References:
1. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5–6):231–7.
2. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57–70.
3. Bhatnagar MK, Arora S, Singh V, Bhattacharjee J. Assessment of insulin resistance using surrogate markers in patients of metabolic syndrome. Diabetes Metab Syndr: Clin Med Rev. 2011;5(1):29–32.
4. Perez-Martinez P, Mikhailidis DP, Athyros VG, Bullo M, Couture P, Covas MI, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: An international panel recommendation. Nutrition Reviews. 2017;75(5):307–26.
5. Li W, Chen D, Peng Y, Lu Z, Kwan MP, Tse LA. Association between metabolic syndrome and mortality: Prospective cohort study. JMIR Public Health Surveill. 2023;9:e44073.
6. Nesci A, Carnuccio C, Ruggieri V, D’Alessandro A, Di Giorgio A, Santoro L, et al. Gut microbiota and cardiovascular disease: Evidence on the metabolic and inflammatory background of a complex relationship. Int J Mol Sci. 2023;24(10):9087.
7. Breban M. Gut microbiota and inflammatory joint diseases. Joint Bone Spine. 2016;83(6):645–9.
8. Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, et al. Human gut microbiota in health and disease: Unveiling the relationship. Front Microbiol. 2022;13:1–14.
9. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183–96.
10. Mostafavi Abdolmaleky H, Zhou JR. Gut microbiota dysbiosis, oxidative stress, inflammation, and epigenetic alterations in metabolic diseases. Antioxidants. 2024;13(8):985.
11. Rohr MW, Narasimhulu CA, Rudeski-Rohr TA, Parthasarathy S. Negative effects of a high-fat diet on intestinal permeability: A review. Adv Nutr. 2020;11(1):77–91.
12. Wang PX, Deng XR, Zhang CH, Yuan HJ. Gut microbiota and metabolic syndrome. Chin Med J. 2020;133(7):808–16.